Published in Fed Proc on July 01, 1967
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Azathioprine (Imuran) administration and the development of malignant lymphomas in NZB mice. Clin Exp Immunol (1968) 2.34
Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol (2008) 1.32
Inhibition of the development of tolerance to morphine in rats by drugs which inhibit ribonucleic acid or protein synthesis. Br J Pharmacol (1970) 1.23
Activities of immunosuppressive agents in vitro. II. Different timing of azathioprine and methotrexate in inhibition and stimulation of mixed lymphocyte reaction. Clin Exp Immunol (1972) 1.12
Assay of thioinosinic acid, an active metabolite of azathioprine, in human lymphocytes. Br J Clin Pharmacol (1980) 1.11
Azathioprine and 6-mercaptopurine (6-MP) suppress the human mixed lymphocyte reaction (MLR) by different mechanisms. Br J Clin Pharmacol (1984) 1.10
Serum immunosuppressive activity of azathioprine in normal subjects and patients with liver diseases. Proc R Soc Med (1972) 1.08
Effects of azathioprine on the human mixed lymphocyte reaction (MLR). Br J Clin Pharmacol (1983) 1.06
Studies on the anti-inflammatory action of 6-mercaptopurine. J Exp Med (1968) 1.06
The thiopurines: an update. Invest New Drugs (2005) 1.05
Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro. Clin Exp Immunol (1973) 0.97
Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol (1976) 0.96
Significance of azathioprine metabolites. Proc R Soc Med (1972) 0.95
Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purine thiol. BMC Biochem (2007) 0.94
6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. Cancer Res (2011) 0.93
IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol (2007) 0.86
Immunosuppressive activity in patients with active chronic hepatitis and primary biliary cirrhosis treated with azathioprine. Gut (1972) 0.85
The effects of azathioprine and levamisole on lymphocyte stimulation. Clin Exp Immunol (1979) 0.85
Mechanisms in the suppression of delayed hypersensitivity in the guinea pig by 6-mercaptopurine. J Exp Med (1973) 0.83
Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms? PLoS One (2013) 0.82
The effect of azathioprine (Imuran) on the cell cycle of promonocytes and the production of monocytes in the bone marrow. J Exp Med (1975) 0.82
Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J Med Chem (2007) 0.81
Cytotoxic properties of a 4-nitroimidazole (NSC 38087): a radiosensitizer of hypoxic cells in vitro. Br J Cancer (1981) 0.81
Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol (2013) 0.80
Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug AraA. Nucleic Acids Res (1989) 0.80
Purines as 'hyper-repressors' of glucose transport. A role for phosphoribosyl diphosphate. Biochem J (1983) 0.79
Effect of 6-thioguanine on Chlamydia trachomatis growth in wild-type and hypoxanthine-guanine phosphoribosyltransferase-deficient cells. J Bacteriol (1992) 0.79
In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase. Drug Metab Dispos (2014) 0.77
Simultaneous Determination of 6-Mercaptopurine and its Oxidative Metabolites in Synthetic Solutions and Human Plasma using Spectrophotometric Multivariate Calibration Methods. Bioimpacts (2011) 0.77
Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism. PLoS One (2017) 0.75
Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors. Bioorg Med Chem (2007) 0.75
In vitro studies of the cell-bound and antibody-mediated immunity evoked by murine renal allotransplants. Influence of presensitization, total body irradiation and immunosuppressive agents. Clin Exp Immunol (1973) 0.75
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature (1978) 9.21
Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem (1978) 5.43
Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol (1979) 4.53
Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother (1979) 2.75
Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol (1980) 2.69
Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol (1966) 2.33
Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem (1981) 2.29
The resolution of active and inactive xanthine oxidase by affinity chromatography. J Biol Chem (1972) 2.22
Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother (1981) 2.21
Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology (1980) 2.18
A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys (1972) 2.16
Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem (1976) 2.14
Human hypoxanthine phosphoribosyltransferase. I. Purification, properties, and specificity. J Biol Chem (1969) 2.01
Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol (1981) 1.92
In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother (1980) 1.87
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem (1970) 1.84
Guanine phosphoribosyltransferase from Escherichia coli, specificity and properties. Biochemistry (1972) 1.77
Mechanism of action and selectivity of acyclovir. Am J Med (1982) 1.67
Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther (1979) 1.52
Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation. J Biol Chem (1979) 1.49
Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl)guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines. J Virol (1981) 1.44
Enzymatic and metabolic studies with allopurinol. Ann Rheum Dis (1966) 1.42
Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother (1980) 1.41
The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother (1983) 1.41
The disposition of acyclovir in different species. J Pharmacol Exp Ther (1981) 1.38
Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J Biol Chem (1979) 1.35
Ribonucleotide reductase induced by herpes simplex type 1 virus. Characterization of a distinct enzyme. J Biol Chem (1983) 1.31
Biological activities of some purine arabinosides. Ann N Y Acad Sci (1975) 1.25
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1997) 1.25
Metabolic basis for the actions of analogs of purines and pyrimidines. Adv Chemother (1965) 1.24
Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med (1968) 1.18
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res (2000) 1.16
Identification of small DNA fragments synthesized in herpes simplex virus-infected cells in the presence of acyclovir. Antimicrob Agents Chemother (1984) 1.13
Formation of nucleotides of (6-14C)allopurinol and (6-14C)oxipurinol in rat tissues and effects on uridine nucleotide pools. Biochem Pharmacol (1973) 1.10
Inhibition of human purine nucleoside phosphorylase. Studies with intact erythrocytes and the purified enzyme. J Biol Chem (1968) 1.07
Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA (1975) 1.06
Thiopurine biology and pharmacology. Trends Pharmacol Sci (1997) 1.04
Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization. J Biol Chem (1967) 1.02
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol (1998) 1.00
2-Fluoroadenosine 3':5'-monophosphate. A metabolite of 2-fluoroadenosine in mouse cytotoxic lymphocytes. J Biol Chem (1976) 0.99
Metabolism of pyrazolo(3,4-d)pyrimidines in Leishmania braziliensis and Leishmania donovani. Allopurinol, oxipurinol, and 4-aminopyrazolo(3,4-d)pyrimidine. J Biol Chem (1979) 0.98
The existence of nonfunctional active sites in milk xanthine oxidase: reaction with functional active site inhibitors. Vitam Horm (1970) 0.98
Rarity of X-linked partial hypoxanthine-guanine phosphoribosyltransferase deficiency in a large gouty population. Ann Intern Med (1972) 0.97
Specificity of adenylosuccinate synthetase and adenylosuccinate lyase from Leishmania donovani. Selective amination of an antiprotozoal agent. J Biol Chem (1979) 0.96
Resistance to inhibitors of dihydrofolate reductase in strains of Lactobacillus casei and Proteus vulgaris. J Gen Microbiol (1966) 0.96
Significance of azathioprine metabolites. Proc R Soc Med (1972) 0.95
Adenine phosphoribosyltransferase from monkey liver. Specificity and properties. J Biol Chem (1969) 0.95
Species differences in the disposition of acyclovir. Am J Med (1982) 0.94
Uptake, distribution, and anabolism of acyclovir in herpes simplex virus-infected mice. Antimicrob Agents Chemother (1982) 0.94
Antileishmanial action of 4-thiopyrazolo (3.4-d) pyrimidine and its ribonucleoside. Biological effects and metabolism. Biochem Pharmacol (1982) 0.93
Inhibition of lymphocyte-mediated cytolysis by adenosine analogs. Biochemical studies concerning mechanism of action. Biochem Pharmacol (1978) 0.92
Modulation of cyclic AMP metabolism by S-adenosylhomocysteine and S-3-deazaadenosylhomocysteine in mouse lymphocytes. Proc Natl Acad Sci U S A (1980) 0.91
The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat. J Pharmacol Exp Ther (1973) 0.90
Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 2. Synthesis and activity of some nucleosides of 4-(alkylamino)-1H-pyrazolo[3, 4-d]pyrimidines. J Med Chem (1982) 0.90
Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro. Am J Med (1982) 0.90
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol (2000) 0.89
Influence of glutamine on the growth of human glioma and medulloblastoma in culture. Cancer Res (1985) 0.88
The chemotherapeutic exploitation of virus-specified enzymes. Adv Enzyme Regul (1980) 0.88
A radioimmunoassay for herpes simplex virus (HSV) thymidine kinase. Virology (1982) 0.87
Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus. Am J Med (1982) 0.87
Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res (1988) 0.86
Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma. Cancer Res (1985) 0.85
Comparative metabolism of a new antileishmanial agent, allopurinol riboside, in the parasite and the host cell. Adv Exp Med Biol (1979) 0.84
The Effects of Antagonists on the Multiplication of Vaccinia Virus in Vitro. Science (1949) 0.82
Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. Cancer Res (1988) 0.82
Purine salvage enzymes in man and Leishmania donovani. Adv Exp Med Biol (1979) 0.82
Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. Br J Cancer (1995) 0.82
Actions of purine analogs: enzyme specificity studies as a basis for interpretation and design. Cancer Res (1969) 0.81
Metabolism of (6-14-c)allopurinollack of incorporation of allopurinol into nucleic acids. Biochem Pharmacol (1975) 0.81
Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 1. Synthesis and activity of some nucleosides of purines and 4-(alkylthio)pyrazolo[3,4-d]pyrimidines. J Med Chem (1982) 0.81
Pharmacokinetics and bioavailability of acyclovir in the dog. J Pharmacol Exp Ther (1981) 0.81
An overview of the role of nucleosides in chemotherapy. Adv Enzyme Regul (1985) 0.80
Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. J Natl Cancer Inst (1989) 0.80
Differential inhibition by azathioprine and 6-mercaptopurine of specific suppressor T cell generation in mice. J Immunopharmacol (1981) 0.80
Preclinical toxicology studies with acyclovir: acute and subchronic tests. Fundam Appl Toxicol (1984) 0.80
Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol (1994) 0.80
Selectivity--key to chemotherapy: presidential address. Cancer Res (1985) 0.80
Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine. Transplantation (1991) 0.80
The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Reproduced from Proc. Natl. Acad. Sci. USA 74, 5716-5720 (1977) Rev Med Virol (1999) 0.79
Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. J Pharmacol Exp Ther (1983) 0.79
Inhibition of lymphocyte-mediated cytolysis by 2-fluoroadenosine--evidence for two discrete mechanisms of drug action. Biochem Pharmacol (1978) 0.78
Mercaptopurine "bioavailability". N Engl J Med (1984) 0.78
Immunosuppressive effects of the S-adenosylhomocysteine hydrolase inhibitor, 3-deazaadenosine. J Immunopharmacol (1982) 0.78
Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res (1990) 0.78
Xanthine phosphoribosyltransferase from Streptococcus faecalis. Properties and specificity. Arch Biochem Biophys (1974) 0.78
Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Cancer Res (1989) 0.78
Chronic allopurinol administration and iron storage in mice. Life Sci (1968) 0.78
Formation of 5'-nucleotides of 6-methylmercaptopurine ribonucleoside in human tissues in vitro. Biochem Pharmacol (1974) 0.78
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemother Pharmacol (1998) 0.78
Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. Radiat Res (1992) 0.78
Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR. Cancer Res (1991) 0.77
Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 3. Synthesis and activity of some nucleosides of 4-[(arylalkenyl)thio]pyrazolo[3,4-d]pyrimidines. J Med Chem (1983) 0.77
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. Cancer Chemother Pharmacol (1991) 0.77
Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol (1980) 0.77
Activation and antiviral effect of acyclovir in cells infected with a varicella-like simian virus. Am J Med (1982) 0.77
Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. Int J Hyperthermia (1992) 0.76
Identification of 6-methylmercaptopurine ribonucleoside 5'-diphosphate and 5'-triphosphate as metabolites of 6-mercaptopurine in man. Cancer Res (1974) 0.76
Pharmacologic and physical agents. Immunosuppressive agents. Transplant Proc (1977) 0.76